Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Evaluating the neutralizing ability of a CpG-adjuvanted S-2P subunit vaccine against SARS-CoV-2 Variants of Concern

Chia-En Lien, Tsun-Yung Kuo, Yi-Jiun Lin, Wei-Cheng Lian, Meei-Yun Lin, Luke Tzu-Chi Liu, Yu-Chi Chou, Charles Chen
doi: https://doi.org/10.1101/2021.03.19.21254000
Chia-En Lien
1Medigen Vaccine Biologics Corporation, Taipei City, Taiwan
2Institute of Public Health, National Yang-Ming Chiao Tung University, Taiwan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tsun-Yung Kuo
1Medigen Vaccine Biologics Corporation, Taipei City, Taiwan
3Department of Biotechnology and Animal Science, National Ilan University, Yilan County, Taiwan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yi-Jiun Lin
1Medigen Vaccine Biologics Corporation, Taipei City, Taiwan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Wei-Cheng Lian
1Medigen Vaccine Biologics Corporation, Taipei City, Taiwan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Meei-Yun Lin
1Medigen Vaccine Biologics Corporation, Taipei City, Taiwan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Luke Tzu-Chi Liu
1Medigen Vaccine Biologics Corporation, Taipei City, Taiwan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yu-Chi Chou
4Biomedical Translation Research Center (BioTReC), Academia Sinica
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Charles Chen
1Medigen Vaccine Biologics Corporation, Taipei City, Taiwan
5Temple University, Philadelphia, PA 19122, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: charles@medigenvac.com
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

Vaccination is currently the best weapon to control the COVID-19 pandemic. However, an alarming number of novel variants termed Variants of Concern (VoC) were found to harbor mutations that diminished the neutralizing capacity of antibodies elicited by the vaccines. We have investigated the neutralizing titers of antibodies from sera of humans and rats immunized with the MVC-COV1901 vaccine against pseudoviruses coated with the wildtype, D614G, B.1.1.7, or B.1.351 spike proteins. Rats vaccinated with two doses of adjuvanted S-2P retained neutralization activities against the B.1.351 variant, albeit with a slight reduction compared to wildtype. Phase 1 vaccinated subjects showed more reduced neutralization abilities against the B.1.351 variant. The study is among the first, to our knowledge, to demonstrate dose-dependent neutralizing responses against VoCs, particularly against B.1.351, from different doses of antigen in a clinical trial for a subunit protein COVID-19 vaccine. The appearance of vaccine escape variants is a growing concern facing many current COVID-19 vaccines and therapeutics. Strategies should be adopted against the ever-changing nature of these variants. The observations of this study grant us valuable insight into preemptive strikes against current and future variants.

Competing Interest Statement

The authors have declared no competing interest.

Clinical Trial

NCT04487210

Funding Statement

No external funding was received.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The protocol has been approved by the 132nd meeting of Research Ethics Committee C of the National Taiwan University Hospital (NTUH) on Aug 3, 2020. The committee is organized under, and operates in accordance with, the Good Clinical Practice guidelines and governmental laws and regulations. Approval by the Ministry of Health and Welfare is mandatory before project implementation. The duration of this approval is six months (Aug 6, 2020 to Feb 5, 2021). The investigator is required to report Serious Adverse Events and Unanticipated Problems in accordance with the governmental laws and regulations and NTUH requirements and apply for a continuing review not less than six weeks prior to the approval expiration date. Chairman of Research Ethics Committee C: Daniel Fu-Chang Tsai, M.D. NTUH-REC No. 202007029MSC Protocol No. CT-COV-11

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

The datasets generated during and analyzed during the current study are available from the corresponding author on reasonable request.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.
Back to top
PreviousNext
Posted March 22, 2021.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Evaluating the neutralizing ability of a CpG-adjuvanted S-2P subunit vaccine against SARS-CoV-2 Variants of Concern
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Evaluating the neutralizing ability of a CpG-adjuvanted S-2P subunit vaccine against SARS-CoV-2 Variants of Concern
Chia-En Lien, Tsun-Yung Kuo, Yi-Jiun Lin, Wei-Cheng Lian, Meei-Yun Lin, Luke Tzu-Chi Liu, Yu-Chi Chou, Charles Chen
medRxiv 2021.03.19.21254000; doi: https://doi.org/10.1101/2021.03.19.21254000
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
Evaluating the neutralizing ability of a CpG-adjuvanted S-2P subunit vaccine against SARS-CoV-2 Variants of Concern
Chia-En Lien, Tsun-Yung Kuo, Yi-Jiun Lin, Wei-Cheng Lian, Meei-Yun Lin, Luke Tzu-Chi Liu, Yu-Chi Chou, Charles Chen
medRxiv 2021.03.19.21254000; doi: https://doi.org/10.1101/2021.03.19.21254000

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Allergy and Immunology
Subject Areas
All Articles
  • Addiction Medicine (179)
  • Allergy and Immunology (433)
  • Anesthesia (99)
  • Cardiovascular Medicine (946)
  • Dentistry and Oral Medicine (178)
  • Dermatology (109)
  • Emergency Medicine (260)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (420)
  • Epidemiology (8978)
  • Forensic Medicine (4)
  • Gastroenterology (419)
  • Genetic and Genomic Medicine (1947)
  • Geriatric Medicine (190)
  • Health Economics (401)
  • Health Informatics (1327)
  • Health Policy (657)
  • Health Systems and Quality Improvement (519)
  • Hematology (212)
  • HIV/AIDS (419)
  • Infectious Diseases (except HIV/AIDS) (10793)
  • Intensive Care and Critical Care Medicine (575)
  • Medical Education (200)
  • Medical Ethics (54)
  • Nephrology (222)
  • Neurology (1824)
  • Nursing (109)
  • Nutrition (272)
  • Obstetrics and Gynecology (352)
  • Occupational and Environmental Health (470)
  • Oncology (997)
  • Ophthalmology (297)
  • Orthopedics (111)
  • Otolaryngology (182)
  • Pain Medicine (126)
  • Palliative Medicine (44)
  • Pathology (265)
  • Pediatrics (579)
  • Pharmacology and Therapeutics (275)
  • Primary Care Research (234)
  • Psychiatry and Clinical Psychology (1895)
  • Public and Global Health (4117)
  • Radiology and Imaging (675)
  • Rehabilitation Medicine and Physical Therapy (366)
  • Respiratory Medicine (548)
  • Rheumatology (224)
  • Sexual and Reproductive Health (190)
  • Sports Medicine (177)
  • Surgery (207)
  • Toxicology (39)
  • Transplantation (109)
  • Urology (80)